This year has delivered plenty of volatility for investors in ASX shares.
But sharp market sell-offs can also create rare opportunities to buy high-quality businesses at far more attractive valuations.
After suffering heavy declines over the past 12 months, these two ASX shares still look well-positioned for long-term growth over the next decade and beyond.
Image source: Getty Images
REA Group Ltd (ASX: REA)
When it comes to dominant Australian digital platforms, REA Group remains one of the market's highest-quality businesses.
The $22 billion ASX share sits right at the centre of Australia's property market through realestate.com.au, giving it a powerful competitive advantage that is incredibly difficult to replicate. Real estate agents need visibility to attract buyers and vendors and REA controls much of that online traffic.
That market dominance has allowed the company to steadily raise prices over time through premium listings, depth products, and advertising services, even during softer housing cycles.
Importantly, it is also an exceptionally scalable business model. Because the platform is digital, incremental revenue tends to flow through to earnings at very attractive margins.
Even amid a difficult share price period, the business itself continues performing strongly. Last week, REA reported revenue from core operations of $398 million for the three months ended 31 March, up 11% from the prior corresponding period. After adjusting for mergers and acquisitions, revenue still increased 6%.
The earnings result was similarly solid. EBITDA excluding associates climbed 11% to $220 million, while operating expenses increased only 5% to $178 million.
Despite those numbers, the ASX share fell another 6% on Thursday and are now down roughly 35% over the past year.
That disconnect between operational performance and share price weakness is exactly what long-term investors often look for.
Broker sentiment also remains supportive. Morgans said it was impressed with the company's strong yield outcome and operating cost guidance. The broker retained its buy rating while slightly trimming its price target to $219, suggesting a 37% upside at the current share price.
Pro Medicus Ltd (ASX: PME)
Another beaten-down ASX growth share catching attention is Pro Medicus.
The healthcare technology company has built a world-class reputation for securing major hospital imaging contracts across the United States. Its Visage imaging platform becomes deeply integrated into hospital radiology workflows, creating powerful switching costs and sticky recurring revenue streams.
That business model continues delivering exceptional financial results. In its HY26 result, Pro Medicus reported revenue growth of 28.4% to $124.8 million, while underlying profit before tax surged almost 30%. Those are elite growth numbers by almost any standard.
Yet despite the strong operational momentum, Pro Medicus shares have been heavily sold off alongside the broader healthcare sector. The ASX share is now down 55% over 12 months and was trading around $121.60 at the time of writing.
For long-term investors, that weakness may present an attractive opportunity. Healthcare imaging demand continues rising globally, while hospitals increasingly require faster and more efficient digital imaging systems. Pro Medicus appears well-positioned to benefit from those long-term structural trends.
Analysts also remain optimistic on the ASX share. Morgan Stanley currently maintains a buy rating on the stock with a $200 price target. That implies potential upside of roughly 65% from current levels.
